TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021
March 05 2021 - 9:00AM
Business Wire
On-demand presentations scheduled at H.C.
Wainwright Global Life Sciences Conference and 33rd Annual ROTH
Conference
Live panel discussion scheduled for March 15th
at 12pm ET
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative drug products based on its patented Thin Film Freezing
(TFF) technology platform, will participate in the H.C. Wainwright
Global Life Sciences Conference and the 33rd Annual ROTH
Conference, held virtually on March 9-10, 2021, and March 15-17,
2021, respectively.
Glenn Mattes, President & CEO of TFF Pharmaceuticals, is
scheduled to give a pre-recorded company presentation at both
virtual conferences.
Additionally, Dr. Dale Christensen, Director of Clinical
Development at TFF Pharmaceuticals, will participate in a panel
discussion at the ROTH Conference on March 15th at 12pm ET. The
discussion, titled Therapeutics Against SARS-CoV-2 – Viral Variants
Will Not Fade Away, will be led by Dr. Jonathan Aschoff, Managing
Director and Senior Research Analyst at ROTH, and Dr. Christensen
will be joined by other leading researchers in the industry.
Recordings of the presentations will be available on-demand to
registered conference attendees and can be accessed in the Investor
Relations section of the TFF Pharmaceuticals website. The Company
will also participate in investor and partnering meetings with
conference attendees at both events.
About TFF Pharmaceuticals’ Thin Film Freezing technology
platform
TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was
designed to improve the solubility and absorption of poorly
water-soluble drugs and is particularly suited to generate dry
powder particles with properties targeted for inhalation delivery,
especially to the deep lung, an area of extreme interest in
respiratory medicine. The TFF process results in a “Brittle Matrix
Particle,” which possesses low bulk density, high surface area, and
typically an amorphous morphology, allowing the particles to
supersaturate when contacting the target site, such as lung tissue.
Based upon laboratory experiments the aerodynamic properties of the
particles are such that the portion of a drug deposited to the deep
lung has the potential to reach as high as 75 percent.
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative drug
products based on its patented Thin Film Freezing, or TFF,
technology platform. Early testing confirms that the TFF platform
can significantly improve the solubility and absorption of poorly
water-soluble drugs, a class of drugs that comprises approximately
one-third of the major pharmaceuticals worldwide, thereby improving
their pharmacokinetics. TFF Pharmaceuticals has two lead drug
candidates: Voriconazole Inhalation Powder and Tac-Lac Inhalation
Powder. The Company plans to add to this pipeline by collaborating
with large pharmaceutical partners. The TFF Platform is protected
by 42 patents issued or pending in the US and internationally. To
learn more about TFF Pharmaceuticals and its product candidates,
visit the Company’s website at https://tffpharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210305005309/en/
Glenn Mattes President and CEO TFF Pharmaceuticals, Inc.
gmattes@tffpharma.com 737-802-1973
Kirk Coleman Chief Financial Officer TFF Pharmaceuticals, Inc.
kcoleman@tffpharma.com 817-989-6358
Investor Relations and Media: Paul Sagan
LaVoieHealthScience psagan@lavoiehealthscience.com 617-865-0041
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Mar 2024 to Apr 2024
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Apr 2023 to Apr 2024